Initiative for Medicines Access & Knowledge I-Mak Inc.

“The 990 is presented and discussed by the board of directors before it is filed with the irs.”

“In connection with any actual or possible conflict of interest, a board member must disclose the existence of the conflict of interest and disclose all material facts. The remaining board or committee members shall decide if a conflict of interest exists. If a conflcit is found to exist, the board member takes a sabbatical, resigns or removes the conflict.”

“The board of directors work with an external compensation firm to review compensation packages of the co-executive directors and to obtain independent comparability data in determining that the compensation is just and reasonable. This process occurs whenever a top executive is hired, when their employment terms are renewed or extended or when their compensation is modified. This process is documented and approved through memorandum with the external firm and any final decisions in board minutes/resolutions.”

“The organization makes its governing documents, conflict of interest policy, and financial statements available to the public upon request.”

“In 2022, i-mak's public education program aimed to make the role of patents central in the drug pricing conversation. I-mak developed and launched the drug patent book, a database with the first comprehensive record of the patents related to america's most popular prescription drugs. To provide resourcess to policymakers, media, and the public, i-mak published a summary of the patent and market data on america's topselling drugs and released its most recent report in the overpatented, overpriced series. I-mak used communications and stakeholder engagement to reveal how structural inequities at every level of the medicines system - brought into sharp focus by the covid-19 pandemic - lead to unnecessary suffering and death for millions of people worldwide. Additionally, i-mak released its "strengthening competition blueprint" that outlines several recommendations for how to strengthen a competitive market through patent and drug regulatory reforms. This "blueprint for reform" was created using i-mak's participatory changemaking model to generate new solutions by bringing people together who are ideologically, geographically, and sectorally diverse to discuss and shape the future of medicines, starting with the patent system.”

“Human resources consultant: program service expenses 0. Management and general expenses 64,874. Fundraising expenses 0. Total expenses 64,874. Administrative consultant: program service expenses 0. Management and general expenses 46,550. Fundraising expenses 0. Total expenses 46,550. Development consultant: program service expenses 0. Management and general expenses 0. Fundraising expenses 35,213. Total expenses 35,213. Communications consultant: program service expenses 254,061. Management and general expenses 0. Fundraising expenses 0. Total expenses 254,061. Technical consultant: program service expenses 94,365. Management and general expenses 0. Fundraising expenses 0. Total expenses 94,365. Legal/scientific consultant: program service expenses 73,299. Management and general expenses 0. Fundraising expenses 0. Total expenses 73,299. Professional development consultant: program service expenses 10,280. Management and general expenses 604. Fundraising expenses 1,209. Total expenses 12,093.”